Asset profile

APG-2575(Lisaftoclax )

Small molecule

Phase 3underway

Evidence outlook · registrational

Acute Myeloid Leukemia: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2028-05-25.

Also in development:Multiple Myeloma · Phase 1/2Systemic Lupus Erythematosus · Phase 1/2

How the evidence outlook works ↗

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2028 (4)
March 2028 (1)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-03 · NCT07505160 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2028 (1)
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-05-25 · NCT06389292 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (1)
Phase 2/3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-06 · NCT07597941 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2028 (1)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-09 · NCT04501120 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (2)
December 2029 (2)
Phase 2/3Acute Myeloid LeukemiaEnrolling by invitation
Est. primary completion 2029-12 · NCT07651163 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2/3Acute Myeloid LeukemiaEnrolling by invitation
Est. primary completion 2029-12 · NCT07651176 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (1)
August 2030 (1)
Phase 3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2030-08-10 · NCT07686965 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.